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Abstract: Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for 
the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to 
serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable 
of downregulating the expression of high affinity IgE receptors on inflammatory cells, as 
well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of 
omalizumab include improvements in respiratory symptoms and quality of life, paralleled by a 
reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids 
and rescue bronchodilators. Omalizumab is relatively well-tolerated, and only rarely induces 
anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for 
patients with severe persistent allergic asthma inadequately controlled by high doses of standard 
inhaled treatments.
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Introduction
Asthma is a complex and heterogenous disease characterized by various immunop-
athologic and clinical phenotypes, based on different patterns of airway inflammation 
involving immune/inflammatory cell types, such as T and B lymphocytes, mast cells, 
eosinophils, basophils, neutrophils, monocytes/macrophages, and dendritic cells, as 
well as structural cellular elements, including both epithelial and mesenchymal cells.1,2 
This widespread respiratory disease, which originates from multiple interactions 
between genetic factors and environmental agents, such as allergens, respiratory 
viruses, and airborne pollutants, is characterized by recurrent episodes of dyspnea, 
wheezing, chest tightness, and cough, usually associated with reversible airflow 
  limitation and an exaggerated bronchoconstrictive response to several different stimuli 
(airway hyper-responsiveness). Asthma constitutes a heavy medical, social, and eco-
nomic burden, and its prevalence is steadily increasing worldwide.3 Indeed, asthma 
affects over 300 million people around the world, and some epidemiologic projections 
estimate that this number will increase further during the next few decades.4 Although 
good control of asthma symptoms can be achieved in a large proportion of patients by 
current standard therapies, mainly based on combinations of inhaled corticosteroids 
and β2-adrenoceptor agonists,5,6 a small percentage (about 5%–10%) of asthmatic 
subjects who are affected by the most severe forms of the disease, although receiving 
the best available inhaled treatments, remain symptomatic and inadequately controlled, 
thus having a poor quality of life. In these patients, asthma symptoms can be further Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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worsened by concomitant comorbidities, including rhinitis, 
sinusitis, gastroesophageal reflux, obesity, and obstructive 
sleep apnea.7 Patients with uncontrolled asthma have a high 
risk of serious morbidity and mortality, thereby representing 
the most severe sector of the overall phenotypic asthma 
spectrum, characterized by the greatest unmet medical needs.8 
Therefore, although being a minority of the global asthmatic 
population, patients with severe asthma are those who use the 
largest share of economic resources and health care services, 
including emergency visits, hospitalizations, and additional 
consumption of drugs utilized for recurrent exacerbations. 
A further social and economic impact of difficult-to-treat 
asthma arises from the frequent loss of school and work days 
due to such a disabling condition. Moreover, patients with 
severe asthma often show a tendency to anxiety and depres-
sion, which can further impair disease control by reducing 
their compliance with prescribed medications.
IgE antibodies are crucially involved in mediating, 
maintaining, and amplifying the allergic cascade.9 Similar 
to the other antibody classes, the IgE structure consists of 
two variable antigen-binding fragments and a receptor-
binding constant portion (Fc). In particular, the IgE molecule 
(molecular weight 190 kD) comprises two identical light 
chains, each made of a variable (VL) and a constant domain 
(CL), as well as two identical heavy chains, each including 
a single-domain variable region (VH) and a constant region 
containing four domains (Cε1, Cε2, Cε3, Cε4). IgE binds to 
its high affinity FcεRI receptor, expressed as an αβγ2 tetramer 
on mast cells and basophils, and as an αγ2 trimer on human 
antigen-presenting cells, monocytes, eosinophils, platelets, 
and smooth muscle cells.10 The IgE-binding function of FcεRI 
is located within the two extracellular domains of its α chain, 
which interact with the two Cε3 domains of IgE, whereas 
the intracellular β-chains and γ-chains are involved in signal 
transduction. At the level of the mast cell surface, adjacent 
allergenic epitopes induce the aggregation of two or more 
FcεRI-bound IgE molecules (cross-linking), thus triggering 
mast cell degranulation.
It is well-known that the propensity to develop exaggerated 
IgE responses to common environmental allergens, referred 
to as atopy, plays a dominant role in the pathologic features 
and clinical manifestations of allergic asthma. Therefore, 
given the key importance of IgE in the immunoinflammatory 
mechanisms underlying atopic asthma, such a condition can 
greatly benefit from IgE-targeted therapies.10–14 In particular, 
according to various studies IgE-mediated positive reactions 
to skin prick tests for common aeroallergens are detectable 
in a percentage of severe asthmatics, ranging from about 
50%–80%.8,15,16
For all these reasons, anti-IgE therapy was included 
in 2006 within step 5 of the Global Initiative for Asthma 
guidelines17 as add-on treatment to inhaled and eventually 
oral corticosteroids, long-acting β2-agonists, and other 
controller medications, such as leukotriene-modifiers and 
theophylline. After being introduced in Australia in 2002 
and US in 2003, utilization of omalizumab, an anti-IgE 
monoclonal antibody, was also approved in 2005 by the 
European Medicines Agency as add-on therapy to improve 
asthma control in adult and adolescent patients (12 years of 
age and above) with severe persistent allergic asthma, who 
have an impaired lung function (forced expiratory volume in 
1 second [FEV1] , 80% predicted) and experience frequent 
daytime symptoms and/or nocturnal awakenings, associated 
with multiple severe exacerbations despite daily high doses 
of inhaled corticosteroids and long-acting β2-adrenoceptor 
agonists. More recently, the use of omalizumab has also been 
approved by European Medicines Agency for children aged 
6 years and older.18 On the basis of such considerations, the 
aim of this review is to discuss the basic pharmacology and 
clinical use of omalizumab.
Mechanism of action and basic 
pharmacology
Omalizumab (molecular weight 150 kD) is a recombinant 
humanized antibody comprising a human IgG framework 
which embeds the complementarity-determining region 
obtained from an anti-IgE antibody raised in mice.19 
Consequently, only about 5% of the humanized monoclonal 
anti-IgE antibody includes residues of murine origin, and 
these structural features of course minimize the risk of 
  developing an immune response towards the nonself   protein.20 
Omalizumab selectively binds with high affinity to the Cε3 
domain of IgE. In particular, one IgE molecule has two 
antigenic sites for omalizumab, and can thus be bound by two 
drug molecules at the same time; similarly, one omalizumab 
molecule has two antigen-binding loci (VH–VL domains of 
IgG), and can thereby interact with two IgE   molecules at the 
same time.21 Therefore, binding of omalizumab to free IgE 
results in the formation of IgE/anti-IgE complexes, which can 
exist as trimers (molecular weight of about 500 kD) or, less 
frequently, as examers (molecular weight about 1000 kD).22 
The small dimensions of these biologically inert IgE/anti-IgE 
immune complexes contribute significantly to their safety. 
Indeed, IgE/omalizumab aggregates are soluble, do not bind Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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complement, and do not precipitate in the kidney, thus they 
do not cause immune complex-related diseases.23 These IgE/
anti-IgE complexes are easily cleared from the circulation by 
the reticuloendothelial system, through the interaction of their 
IgG component with the Fcγ receptors of the hepatic sinusoi-
dal endothelial cells.22 IgE, as well as the IgG omalizumab, 
can freely cross capillaries, thereby distributing between the 
vascular and the extravascular compartments. On the contrary, 
the IgE/omalizumab aggregates do not   diffuse through capil-
lary walls and are also characterized by a marked stability, 
due to the high affinity of omalizumab for IgE. Because of 
these features, IgE/omalizumab immune complexes remain 
and accumulate where they are generated, namely in either 
the blood circulation or local tissues, such as the airways and 
nasal mucosa.21
The Cε3 domain of IgE is the binding site shared by both 
FcεRI and FcεRII/CD23 receptors.24 The latter, expressed 
by B lymphocytes, monocytes, eosinophils, and epithelial 
cells, are structurally characterized by an extracellular 
trimeric α-helical coiled-coil “stalk”, three C-type lectin 
“head domains”, and the C-terminal tails.10 The head domain 
interacts with the outer side of an IgE Cε3 domain in a Ca2+-
dependent manner.21 The main consequences of FcεRII/
CD23 activation include upregulation of IgE synthesis 
and facilitation of B cell-operated antigen presentation to 
T lymphocytes. Therefore, the interaction of omalizumab 
with IgE will prevent the latter from binding to both FcεRI 
and FcεRII/CD23 expressed by several different cell types 
(Figure 1), thus interrupting the allergic cascade.21 This 
implies that omalizumab can interfere with biological 
functions mediated by the stimulation of both high-affinity 
and   low-affinity IgE receptors. Blocking IgE binding to 
FcεRI on mast cells and basophils inhibits allergen-induced 
degranulation, thus   preventing histamine and tryptase 
release, and also affects lipid mediator production and 
cytokine/chemokine gene expression. Moreover, blocking 
IgE binding to FcεRI receptors also reduces FcεRI expres-
sion on basophils by approximately 97%, which correlates 
with a decrease in responsiveness of basophils and mast 
cells to antigen challenge.20 It can thus be inferred that 
IgE is able to upregulate the synthesis of its own high-
affinity receptors. Furthermore, binding of omalizumab to 
circulating IgE reduces free serum IgE   levels by 96%–99%.25 
Omalizumab may also be able to suppress new IgE pro-
duction, probably by inhibiting IgE interactions with the 
FcεRII/CD23 receptors expressed on IgE-switched B cells. 
A further mechanism contributing to the reduction of IgE 
synthesis may be secondary to an omalizumab-dependent 
decrease in the production of IgE-switching cytokines, such 
as interleukin-4 and interleukin-13. In addition to binding 
omalizumab, IgE molecules within the immune complexes 
formed by this drug can still bind allergens (at the VL–VH 
domains), thereby neutralizing some of the antigenic 
stimuli.20 In fact, omalizumab-linked IgE antibodies cannot 
interact further with their receptors, thus potentially acting as 
protective agents against incoming allergens, which in this 
way will be trapped and prevented from reaching residual 
FcεRI-bound IgE on mast cells. Furthermore, by inhibit-
ing IgE binding to FcεRI receptors expressed on dendritic 
cells,   omalizumab can reduce the efficiency of antigen 
presentation to T   lymphocytes. Omalizumab cannot bind to 
receptor-bound IgE and, consequently, does not mimic the 
IgE cross-linking induced by allergens, thus being largely 
nonanaphylactogenic in clinical use.
Practical use and overview  
of clinical studies
The dosage of omalizumab can be determined by taking 
into consideration serum baseline levels of total IgE and 
the patient’s body weight.26 Indeed, by matching these two 
parameters according to the currently available dosing tables, 
it is possible to achieve, with regard to the omalizumab/
Omalizumab
Binds to circulating 
IgE decreasing
cell-bound IgE
Expression of high 
affinity receptors
FceRI
Tissue
infiltration
Dendritic cell
FceRI
Mast cell/basophil
Eosinophil
Plasma cell
Mediator 
release
Allergic inflammation
Asthma symptoms and exacerbations
Figure  1  Mechanism  of  action  of  omalizumab.  Omalizumab  binds  to  ige,  thus 
forming immune complexes that reduce levels of circulating free ige and prevent 
their interactions with high-affinity IgE receptors (FcεRi) expressed by dendritic 
cells,  mast  cells,  basophils,  and  eosinophils.  As  a  consequence,  ige-dependent 
antigen presentation, mast cell/basophil degranulation, and eosinophil infiltration 
are inhibited. Anti-ige therapy with omalizumab also results in decreased FcεRi 
expression.  All  these  effects  are  responsible  for  a  reduction  of  allergic  airway 
inflammation, as well as of related asthma symptoms and exacerbations.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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IgE ratio, the large molar excess (ranging from about 7:1 
to approximately 15:1) required to optimize the efficacy of 
anti-IgE therapies. Utilization of omalizumab is currently 
approved only for allergic asthmatic patients with total plasma 
IgE levels ranging from 30 to 1500 (European Union) or from 
30 to 700 (US) IU/mL, and dosing tables approximately 
reflect the use of the following formula: 0.016 mg/kg per IU/
mL of IgE per 4 weeks. After subcutaneous administration, 
omalizumab achieves a bioavailability of 62%, then reaches 
its peak serum concentration within 7–8 days and has a 
half-life of 19–22 days.27
Omalizumab binds circulating free IgE regardless 
of antigen specificity, thereby being potentially useful 
for atopic disorders caused by either perennial or seasonal 
allergens, as well as by multiple sensitizations.28 Unlike IgE, 
which has a half-life of 1–2 days in humans, omalizumab 
circulates similarly to human IgG1 antibodies, with a half-
life of about 21 days even when it binds IgE thus forming 
trimeric or exameric complexes.29 Due to these pharma-
cokinetic properties, omalizumab is usually administered 
subcutaneously every 4 weeks. Shorter intervals are chosen 
only for practical reasons when patients require relatively 
high drug doses. In fact, because each vial of omalizumab 
contains 150 mg, in order to avoid multiple subcutaneous 
injections at the same time, subjects needing more than 
300 mg monthly are treated every 2 weeks. After a single 
subcutaneous injection, omalizumab induces an 84%–99% 
reversible reduction of unbound serum IgE, low levels of 
which last for 4–6 weeks.30 Clinical responses to omalizumab 
treatment are variable and strictly individual. Currently, an 
overall physician’s evaluation of the effects of omalizumab 
is recommended after 16 weeks of therapy.31 In this regard, 
Bousquet et al have recently shown, basing their observa-
tions on physicians’ global evaluation of treatment effective-
ness, that patient responsiveness to omalizumab detected at 
week 16 persisted at week 32.32 However, among 71 allergic 
asthmatics who did not exhibit a clinical response within 
the first 16 weeks of treatment with omalizumab added to 
optimized asthma therapy, 27 responded to omalizumab 
after a further 16 weeks of treatment. This suggests that, by 
prolonging the initial observational time, it could be possible 
to extend the therapeutic benefits of omalizumab also to a 
subgroup of potential “late responders”, incorrectly classi-
fied as nonresponders on the basis of a 16-week period of 
clinical evaluation.
The first clinical studies showed that, after 9 weeks of 
treatment, omalizumab was able to inhibit both early and 
late asthmatic responses triggered by allergen inhalation.33 
Since then, several multicenter, randomized, double-blind, 
placebo-controlled Phase III trials have been carried out in 
adolescents and adults with moderate-to-severe asthma.34–39 
Omalizumab has been given in addition to stable treatment 
with inhaled corticosteroids and other anti-asthma drugs. 
Taking together the results of these studies, fewer asthma 
exacerbations, improvements in asthma symptoms and 
quality of life, and decreased requirements for both inhaled 
corticosteroids and rescue bronchodilators were observed in 
patients treated with omalizumab compared with placebo.40–42 
Moreover, in comparison with placebo-treated asthmatics, 
omalizumab-treated patients had fewer hospitalizations, 
unscheduled outpatient visits, and emergency room visits. 
Overall, patients who benefited most from omalizumab 
treatment were those with the poorest lung function, and 
receiving the highest inhaled corticosteroid doses. Therefore, 
omalizumab exerted its greatest effects in severe asthma, thus 
being particularly useful as an add-on treatment option for 
patients whose disease was not well controlled.
In particular, the Busse trial included patients with 
severe allergic asthma, whose disease exacerbations were 
significantly decreased by omalizumab during two study 
phases, including inhaled corticosteroid treatments with 
stable or reduced doses, respectively.34 In addition, a higher 
percentage of patients receiving omalizumab than those 
on placebo were able to reduce their inhaled corticosteroid 
intake. These findings were also confirmed by Solér et al and 
Holgate et al, who enrolled subjects with moderate-to-severe 
allergic asthma whose symptoms were not well controlled by 
regular therapy with inhaled corticosteroids.35,36 The SOLAR 
(Study of Omalizumab in comorbid Asthma and Rhinitis) 
study was designed to test the effects of omalizumab in 
concomitant allergic asthma and rhinitis.37 During a 28-week 
treatment with omalizumab, both adolescents and adults 
with moderate-to-severe asthma and moderate-to-severe 
persistent rhinitis were investigated. Omalizumab elicited 
significant improvements in quality of life related to both 
asthma and rhinitis, assessed by the Asthma Quality-of-Life 
Questionnaire and Rhinitis Quality-of-Life Questionnaire. 
These results are very interesting because of the frequent 
association between asthma and rhinitis, two allergic diseases 
linked by reciprocal pathogenic connections.
One of the most important studies to evaluate the clinical 
effects of omalizumab was INNOVATE (Investigation of 
Omalizumab in Severe Asthma Treatment).39 This study 
included 419 allergic patients aged 12–75 years with 
severe persistent asthma, from 108 centers in 14 countries. 
Participating subjects had decreased lung function (FEV1 Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
53
Omalizumab in management of asthma
41%–80% predicted at randomization), associated with 
a recent history of clinically significant exacerbations. In 
particular, patients had experienced an average of 2.1 exac-
erbations per year, and 67% were considered to be at risk of 
asthma-related mortality, assessed on the basis of emergency 
room visits, hospitalizations, or intubations in the previous 
year. Symptom control was not satisfactory, despite stable 
inhaled therapy with relatively high doses of corticosteroids 
and long-acting β2-agonists. In addition, an average of 
31 school/work days had been missed in the previous year. 
Following an 8-week run-in phase, patients were randomized 
in a double-blind manner to receive 28 weeks of treatment 
with either omalizumab or placebo as add-on treatment 
to 2002 Global Initiative for Asthma step 4 therapy. The 
results of INNOVATE show that, when compared with 
placebo (210 patients), omalizumab (209 patients) sig-
nificantly decreased the numbers of emergency visits, as 
well as severe asthma exacerbations requiring unscheduled 
systemic corticosteroids. Omalizumab also elicited a clini-
cally meaningful improvement in quality of life, evaluated 
by the Asthma Quality-of-Life Questionnaire (.0.5 points). 
Furthermore, with respect to placebo, omalizumab produced 
significant improvements in both asthma symptom score 
and peak expiratory flow. Treatment with omalizumab was 
considered to be globally more effective than placebo by both 
the patients and the investigating physicians.
The efficacy of omalizumab in adults, adolescents, 
and children with moderate-to-severe asthma has been 
further confirmed by a recent meta-analysis of eight placebo-
controlled studies in at least 3000 patients and published 
between 2001 and 2009.43 This systematic review considered 
reductions of steroid use and of asthma exacerbations as the 
primary outcomes; secondary outcome measures included 
lung function, use of rescue medication, asthma symptoms, 
and health-related quality of life. Two further recent placebo-
controlled trials have confirmed the efficacy of omalizumab. 
In the first one, including 850 patients aged 12–75 years, 
Hanania et al showed that, when compared with placebo, 
48 weeks of treatment with omalizumab significantly 
decreased asthma symptoms and exacerbations, as well as the 
mean daily number of albuterol puffs.44 Moreover, Busse et al 
have recently shown in 419 inner city children, adolescents, 
and young adults with persistent allergic, moderate-to-severe 
asthma, that addition of omalizumab to guideline-based 
therapy for 60 weeks further improved asthma control, nearly 
eliminated seasonal peaks in exacerbations, and also reduced 
the need for inhaled corticosteroids.45 Furthermore, the 
globally favorable pharmacodynamic pattern of omalizumab 
has also been corroborated by several Phase IV postmarketing 
surveillance trials in patients affected by severe persistent 
allergic asthma treated with omalizumab for 5–12 months 
in real-life practice in France, Germany, Belgium, and 
Italy.46–50
One of the most important questions related to omalizumab 
therapy refers to its duration, ie, how long should this treatment 
last? Given the unusual mechanism of action of omalizumab, 
a tentative answer could be “forever”. Indeed, after a few 
months of treatment, discontinuation of omalizumab in atopic 
subjects resulted in a return to the pretreatment clinical state, 
due to a relatively rapid (within months) rise in free serum 
IgE levels, associated with repopulation of basophil surfaces 
with both IgE and FcεRI receptors.51 More recently, it has 
also been shown that either a dose reduction of omalizumab 
therapy or its complete cessation leads to increases towards 
baseline levels of both free serum IgE concentrations and 
allergen-specific skin prick test reactivity, evaluated as 
wheal-and-flare reactions.52 Medical practice also suggests 
that if omalizumab treatment is interrupted for whatever 
reason, asthma symptoms and exacerbations relapse within 
a few months. However, it has been reported that 6 years of 
treatment with omalizumab induce durable improvement in 
asthma symptoms and lung function, which was maintained 
in 14 of 18 patients for periods of 12–14 months after drug 
withdrawal.53 This persistent asthma control was paralleled by 
a downregulation in basophil activity, still detectable 1 year 
after interruption of omalizumab administration. This report 
suggests that anti-IgE therapy can induce long-term remission 
of the allergic state, possibly by inhibiting IgE production 
and depleting IgE-committed B memory cells.21 Of course, 
further studies are required to verify whether omalizumab 
should be prescribed lifelong or as a relatively long-term 
course. Although the optimal duration of omalizumab 
treatment remains unclear, there is no doubt that the injections 
need to be continued for very long periods of time.
Another problem related to the use of this drug is its 
high cost. However, if omalizumab treatment is restricted 
to selected patients with severe persistent and uncontrolled 
allergic asthma, who respond within 16 weeks with a 
marked improvement in disease control, this therapy could 
be cost-effective.40 This inference from clinical practice 
has been confirmed by an analysis of the incremental 
cost-effectiveness ratio of adding omalizumab to standard 
therapy,54 based on data obtained from the real-life, 1-year 
randomized ETOPA trial.38 To determine the incremental 
cost-effectiveness ratio for omalizumab, the cost/quality-
adjusted life year ratio was calculated. Canada was used Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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as the reference country, and only subjects receiving high 
doses of inhaled corticosteroids plus long-acting β2-agonists 
were considered. Based on these reliable criteria, the 
authors of this analysis concluded that “omalizumab add-on 
therapy in patients with severe persistent asthma results in 
a cost-per-QALY ratio that compares favorably with other 
uses of scarce healthcare resources that are recommended 
by national reimbursement bodies and could be considered 
cost-effective”.54 However, this analysis referred to a small 
open-label study, and was limited to asthmatic subjects who 
were responsive to omalizumab. The results obtained from 
the multinational INNOVATE study appear to be more 
reliable, and show that the cost of omalizumab was offset 
by improved quality of life and had an attractive incremental 
cost-effectiveness ratio in patients with severe allergic asthma 
who remained symptomatic and had an increased risk of 
acute exacerbations despite best available standard care.55,56 
On the other hand, further comparative economic evaluations 
of the cost-effectiveness of omalizumab have confirmed that, 
in patients with severe persistent allergic asthma, add-on 
therapy is comparable with or more favorable than other 
biologic treatments for chronic disorders, such as rheumatoid 
arthritis, Crohn’s disease, and multiple sclerosis.57 These 
considerations are consistent with the conclusions of a more 
recent study, the results of which suggest that, from the US 
payer perspective, the cost-effectiveness of omalizumab may 
be similar to other biologics. Moreover, cost-effectiveness 
improves when a 16-week assessment of response is used 
to guide decisions regarding long-term treatment.58 This 
economically advantageous utilization of omalizumab is thus 
linked to its sparing effect on the heavy burden of resources 
depleted by patients with the most severe forms of asthma.
With regard to the effects of omalizumab on lung function, 
inconsistent data have been reported by various clinical 
trials.40 Indeed, a decrease in free IgE does not necessarily 
affect FEV1 and FEV1/forced vital capacity ratio.59 Therefore, 
the effects of omalizumab on FEV1 are quite controversial, 
and many studies have shown no significant change in this 
functional parameter.40 However, some increases in FEV1 
have been occasionally recorded after several weeks of 
treatment with omalizumab.29,38 Furthermore, according to 
a recent open-label study performed in patients with severe 
uncontrolled allergic asthma randomized to receive best 
standard anti-asthma therapy with or without omalizumab, 
a significant increase in percentage predicted FEV1 has been 
observed throughout a 1-year period of anti-IgE treatment 
in comparison with control values.60 Moreover, there may 
be an association between the reduction in exacerbation 
frequency elicited by omalizumab and the recorded 
improvement of airflow limitation. This observation is 
consistent with the reported relationship between recurrence 
of asthma exacerbations and deterioration of lung function.61 
In particular, the exacerbation-prone phenotype of asthma 
may be characterized by a vicious pathophysiologic circuit 
sustained by exacerbation-driven inflammation leading to 
bronchial narrowing, which in turn predisposes to repetitive 
exacerbation cycles. This self-perpetuating airway injury 
can thus be interrupted by omalizumab. Controversial 
findings have also been reported with regard to the effects of 
omalizumab on bronchial hyper-responsiveness. In particular, 
omalizumab does not seem to affect the airway response to 
methacholine.62,63 However, bronchoconstrictive effectors 
that act directly on airway smooth muscle are not the most 
suitable stimuli for testing the effects of omalizumab on 
bronchial hyper-responsiveness. Indeed, after 4 weeks 
of treatment, omalizumab significantly attenuated the 
airway response to inhaled adenosine 5′monophosphate 
(AMP) in subjects with mild-to-moderate allergic asthma.63 
AMP-induced bronchoconstriction is due to stimulation 
of adenosine A2B receptors located on mast cells, so the 
bronchoprotection against AMP afforded by omalizumab 
is probably dependent on its ability to inhibit mast cell 
activation synergistically triggered by allergens and other 
degranulating agents like AMP.
Very interesting also are the effects of omalizumab 
on various markers of airway inflammation. During 
the steroid reduction phase of a pediatric study carried 
out in allergic asthmatic children, when compared with 
placebo, omalizumab was able to maintain the fractional 
concentration of exhaled nitric oxide (a reliable noninvasive 
biomarker of bronchial inflammation) at significantly lower 
levels.64 These findings have also been recently confirmed 
by another study which demonstrated that, compared with 
placebo, omalizumab reduced fractional concentration of 
exhaled nitric oxide levels during an observation period 
of 48 weeks.44 Moreover, omalizumab was also shown to 
be capable of decreasing eosinophil numbers in peripheral 
blood,65 as well as in induced sputum and bronchial biopsies.62 
This effect of omalizumab is likely due to the induction of 
apoptosis in eosinophils. In fact, omalizumab can increase 
the numbers of eosinophils stained by the apoptotic marker 
annexin V , and this effect is paralleled by an omalizumab-
dependent decreased synthesis of eosinophil survival factors, 
such as granulocyte-macrophage colony-stimulating factor.66 Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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In particular, peripheral blood eosinophils are currently 
believed to be reliable inflammatory biomarkers, and useful 
for monitoring the anti-inflammatory effects of omalizumab. 
In this regard, it is remarkable that a recent pooled analysis 
of data from several trials and involving patients with 
moderate-to-severe persistent allergic asthma treated with 
omalizumab, has found some degree of correlation between 
an omalizumab-induced decrease in peripheral blood 
eosinophils and various clinical and functional outcomes; 
the latter included a reduced requirement for management 
of exacerbations with oral steroid bursts, an increased FEV1, 
and a positive global evaluation of treatment effectiveness 
by the investigators.67
Safety
Overall, omalizumab is well-tolerated, and the most frequent 
adverse events are local injection site reactions, usually 
manifesting as warmth, erythema, swelling, bruising, and 
occasional urticaria-like eruptions. Other relatively frequent 
adverse effects include headache, fatigue, and nausea. The 
pivotal Phase III clinical trials have shown that the frequen-
cies of adverse events were similar between the omalizumab 
and control groups; the majority of unwanted side effects 
were of short duration and mildly to moderately severe.68 
This side effect profile has been confirmed by real-life studies 
which have made it possible to monitor omalizumab-treated 
patients for up to 3 years.46
Although omalizumab is considered to be a nonana-
phylactogenic antibody, anaphylactic and anaphylactoid 
reactions have been sporadically reported. Indeed, IgE- or 
IgG-mediated hypersensitivity reactions against the small 
murine portion of the omalizumab molecule can occur. 
Moreover, although the excipients (sucrose, L-histidine 
hydrochloride monohydrate, L-histidine, polysorbate 20) 
present in omalizumab preparations are generally consid-
ered to be safe, remote reactions to these components can 
occur.69 In particular, both in vitro and in vivo immunologic 
evaluations of two patients who experienced anaphylaxis 
after 1 year of omalizumab treatment concluded that the 
likely cause was the excipient polysorbate.70 In order to 
address these problems, the Omalizumab Joint Task Force 
was formed at the 2007 annual meeting of the American 
Academy of Allergy, Asthma and Immunology, to review 
the data on anaphylaxis and anaphylactoid reactions reported 
by Phase III clinical trials and postmarketing surveillance 
studies. Omalizumab Joint Task Force members inferred 
that, among 39,510 patients receiving omalizumab between 
June 1, 2003 and December 31, 2005, 35 manifested 41 
episodes of anaphylaxis associated with omalizumab, cor-
responding to an anaphylaxis reporting rate of 0.09%.69 
These episodes included increased asthma symptoms and 
urticaria, shortness of breath, tongue swelling, watery itchy 
eyes, and subjective sensations of throat closing. All patients 
responded to anti-anaphylactic treatment, and there were no 
fatalities or respiratory failures requiring intubation. Among 
the 41 reported anaphylactic events, timing information 
was available for only 36 episodes. Considering the latter, 
22 (61%) reactions occurred in the first 2 hours after one of 
the first three doses, whereas five of the episodes occurring 
after the fourth or later doses took place within 30 minutes. 
Therefore, an observation period of 2 hours for the first three 
injections, and of 30 minutes for the following doses would 
have made it possible to detect 75% of these anaphylactic 
reactions. Moreover, advising patients to be equipped with 
an epinephrine autoinjector will probably allow management 
of anaphylactic events occurring outside the recommended 
observation period.69
Given the role played by IgE in immune defense against 
parasitic infestation, the risk of developing such infections 
could be associated with the use of anti-IgE therapies. 
However, evolutionary theories suggest that although IgE is 
very important in protecting animals and even humans living 
in primitive habitats, these antibodies seem to have become 
nonessential in many regions of the world characterized by 
relatively clean household and community environments. On 
the other hand, according to the results of a study carried out 
in allergic subjects resident in poor urban areas of Brazil and 
at high risk of helminthic infections, omalizumab appeared 
to be effective and safe, although its use was associated with 
a slightly increased risk of parasitic infections.71 Therefore, 
caution should be recommended in the use of omalizumab 
by patients at high risk of helminthic infections, particularly 
when living in or travelling to areas where these infections 
are endemic. In the event of unsatisfactory responses to 
conventional antihelminthic treatments, discontinuation of 
omalizumab should be considered.
A major concern arises from the small increase in the num-
bers of malignancies, including tumors of the breast, prostate, 
and parotid gland, as well as a case of lymphoma detected 
in initial studies of omalizumab-treated patients compared 
with control groups.30 However, no difference in cancer inci-
dence was found between subjects undergoing omalizumab 
therapy and the general population. Furthermore, most cancers 
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therapy, thus suggesting that they were likely pre-existing, 
because drug-induced malignancies usually develop after lon-
ger exposures. Therefore, on the basis of these considerations, 
also including the diversity in the types of neoplasms observed, 
panels of blinded and independent oncologists concluded that 
no causal relationship between omalizumab administration and 
cancer development can be hypothesized.
Some sporadic cases of Churg–Strauss syndrome possibly 
related to omalizumab treatment have been reported.72–74 
Similar to previous observations regarding the use of 
leukotriene receptor antagonists,75 it is not yet clear whether 
these drugs, including omalizumab, may cause Churg–
Strauss syndrome, or simply unmask pre-existing latent 
disease because they facilitate corticosteroid tapering and 
withdrawal. However, at least one report refers to a patient 
who had only received two short courses of oral corticos-
teroids in the year before omalizumab administration was 
initiated.73 This patient experienced a paradoxical increase in 
blood eosinophil count during treatment with omalizumab, 
even though this drug is a potential inducer of eosinophil 
apoptosis. Further pharmacovigilance studies are of course 
needed to ascertain if the development of Churg–Strauss 
syndrome can be induced by omalizumab. Caution is rec-
ommended when considering use of omalizumab in patients 
affected by this relatively rare vasculitis.
More recently, some concerns have been raised by 
the US Food and Drug Administration about the potential 
occurrence of cardiovascular and cerebrovascular side 
effects in patients treated with omalizumab, when compared 
with subjects not receiving this drug.76 However, the Food 
and Drug Administration is not recommending any changes 
to the prescribing information for omalizumab, and is not 
advising patients to stop taking this drug. In particular, 
because it has been hypothesized that omalizumab could 
induce an increase in ischemic heart disease, arrhythmias, 
cardiac failure, pulmonary hypertension, and thrombotic 
events, an ongoing observational study (EXCELS, 
Evaluating Clinical Effectiveness and Long-Term Safety 
in Patients With Moderate to Severe Asthma) is evaluating 
the long-term safety profile of omalizumab in patients 
followed for 5 years. However, a recent systematic analysis 
of eight placebo-controlled trials in 3429 participants 
has not detected increased cardiovascular risk due to 
the use of omalizumab.43 On the contrary, four cases of 
adverse cardiovascular effects, including angina pectoris, 
tachyarrhythmia, and atrial fibrillation were reported in 
the placebo groups. Moreover, a case of cardiac arrest also 
occurred in the placebo group.
Preliminary studies including small numbers of women 
who have received omalizumab during pregnancy have not 
detected any significant difference in comparison with control 
groups with regard to normal deliveries and spontaneous 
abortion rates.77
Therefore, the current consensus among clinicians is 
that the use of omalizumab is safe. However, as with any 
  relatively new class of drugs, continued surveillance is 
needed as its utilization in real life practice continues to 
grow, thus involving progressively increasing numbers of 
patients.78
Future perspectives
Although omalizumab is very effective in reducing allergic 
bronchial inflammation, its potential effects on airway 
remodeling, which is a key feature of severe asthma, are 
still not well understood.79 However, it is noteworthy that 
high-affinity IgE receptors are also expressed on the surface 
of structural airway cells, such as bronchial epithelial cells. 
The latter are indeed actively involved in the production of 
growth factors playing a central role in remodeling events in 
the airways of patients with asthma,80 especially those with the 
most severe disease phenotypes. Therefore, omalizumab could 
potentially interfere with the synthetic activity of bronchial 
epithelium, which contributes remarkably to the airway 
remodeling process. In this regard, it has been reported that 
omalizumab was able to decrease significantly the production 
of transforming growth factor beta by bronchial epithelial 
cells cultured in a medium containing atopic serum from a 
dust mite-sensitive patient and exposed to the stimulatory 
actions of interleukin-1β or ragweed allergen.81 Omalizumab 
could thus inhibit the fibrotic effects exerted by transforming 
growth factor beta in asthmatic airways via this mechanism. 
Furthermore, it has recently been reported that omalizumab 
can significantly decrease the concentration of endothelin-1 in 
the exhaled breath condensate of patients with severe persistent 
allergic asthma.82 Endothelin-1 is a peptide mediator produced 
by vascular endothelial cells, bronchial epithelial cells, and 
mast cells, and is actively involved in the pathogenesis of 
airway structural changes, such as subepithelial fibrosis and 
proliferation of bronchial smooth muscle cells. On the other 
hand, in experimental murine models of allergic asthma, 
omalizumab has been shown to reduce airway wall thickness, 
mucous gland metaplasia, and subepithelial fibrosis. On the 
basis of these findings, an ongoing study (EXPLORE) is 
investigating if omalizumab may be effective in preventing 
airway structural changes in asthmatic patients, in bronchial 
biopsies performed at different time points over 78 weeks.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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Conclusion
Availability of omalizumab in medical practice represents a 
remarkable advance in the management of severe persistent 
allergic asthma. Omalizumab makes it possible to improve 
disease control in many atopic patients who, although 
receiving optimized standard therapy, still experience a 
persistence of respiratory symptoms and a high frequency 
of asthma exacerbations. The efficacy of omalizumab 
in reducing allergic airway inflammation and its clinical 
manifestations have been demonstrated in several trials, 
including real-life investigations. With the exception of a 
few sporadically reported relevant side effects, the drug 
appears to be safe. However, future investigations are 
needed in order to evaluate further the long-term actions of 
omalizumab. Moreover, given the wide expression of IgE 
receptors on cross-talking immune/inflammatory and airway 
resident cells, it will be very interesting to explore whether 
anti-IgE therapy may eventually prevent and/or attenuate the 
development of immune-mediated airway remodeling and 
progressive functional decline, thus possibly affecting the 
natural history of severe asthma.
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